Unitron Medx

Unitron Medx has been active since 2011 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €7,453 and a net result of -€3,587. Equity is shrinking by about 3% per year across the filed financial years. Its solvency ranks better than 19% of 146 sector peers (NACE 26, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).